Vtama in Psoriasis Patients Being Treated With Biologics.

Phase 4

Completed

• Conditions: Psoriasis
• Interventions: Drug: Tapinarof

• Registration Number: NCT06103695
• Lead Sponsor: Psoriasis Treatment Center of Central New Jersey

Brief Summary

Open label study to assess 12 weeks of add-on VTAMA® (tapinarof) Cream, 1% QD in patients with ≥3% BSA who have received biologic therapy for at least 24 weeks.

Detailed Description

Not available

Study Timeline

• Study Start: 2023-02-27
• Status Verified: 2023-10
• Primary Completion: 2023-10-18
• Study Completion: 2023-10-18
• Study First Submitted: 2023-10-19
• Study First Submitted QC: 2023-10-19
• Last Update Submitted: 2023-10-19
• Study First Posted: 2023-10-27
• Last Update Posted: 2023-10-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1. Male or female adult ≥ 18 years of age;
2. Diagnosis of chronic plaque-type
3. Patient with ≥3% BSA
4. Patient has been treated with biologic for a minimum of 24 weeks
5. Able and willing to give written informed consent prior to performance of any study-related procedures.

Read More

Exclusion Criteria

1. ≤3% BSA
2. Patient not receiving biologic agent, or receiving biologic agent <24weeks

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Vtama	Tapinarof	open label Vtama

Primary Outcome Measures

Name	Time	Method
Body surface area ≤1%	12 weeks	Patients who achieve body surface area of ≤1%

Trial Locations

Locations (1)

Schweiger Derm Group; 🇺🇸 East Windsor, New Jersey, United States